A Selective and Sensitive Method Development and Validation for Impurity Quantification in Cysteamine Bitartrate Bulk...

Area of Science:

• Analytical Chemistry
• Pharmaceutical Analysis

Background:

• Cysteamine bitartrate is a crucial pharmaceutical agent.
• Ensuring the purity and quality of pharmaceutical formulations is paramount for patient safety and therapeutic efficacy.
• Impurity profiling is a critical aspect of pharmaceutical development and quality control.

Purpose of the Study:

• To develop and validate a simple, selective, and sensitive analytical method for quantifying impurities in cysteamine bitartrate formulations.
• To establish a robust method suitable for routine quality control of cysteamine bitartrate drug products and substances.

Main Methods:

• Reverse-phase high-performance liquid chromatography (RP-HPLC) was employed using a Shim-pack Sceptre HD-C18 column.
• A gradient elution program with a mobile phase consisting of a hexane sulfonic acid buffer and acetonitrile was utilized.
• The method was optimized for temperature (40°C), flow rate (0.8 mL/min), wavelength (200 nm), and injection volume (10 μL).

Main Results:

• The developed RP-HPLC method demonstrated excellent linearity (R2 > 0.999) and specificity.
• High accuracy (97%-103% recovery) and precision (≤1.0% RSD) were achieved.
• The method proved to be stable and peak homogeneous under various stress conditions (acid, base, oxidation, heat, photolysis) as per ICH guidelines, with a limit of detection (LOD) of 0.3 μg/mL and a quantification limit (LOQ) of 1.0 μg/mL.

Conclusions:

• The validated RP-HPLC method is simple, selective, sensitive, accurate, precise, and robust for impurity quantification in cysteamine bitartrate.
• This analytical method meets the stringent requirements of ICH and USP guidelines for pharmaceutical quality control.
• The method's reliability ensures the consistent quality and safety of cysteamine bitartrate formulations.